ARTICLE | Company News
Zealand Pharma, Wyeth deal
May 5, 2003 7:00 AM UTC
WYE will co-develop ZP123 from Zealand to treat arrhythmias and other cardiovascular diseases. The ZP123 peptide acts on gap junctions, which help maintain normal heart rhythm. The partners will colla...